We investigated 15 patients with one or more transient ischemic attacks (TIAs) hi the internal carotid artery territory within the month following the most recent TIA. Cerebral blood flow (CBF) was measured by single-photon emission computed tomography, using intravenous xenon-133 before and after injection of 1 g acetazolamide. Six patients had severe carotid stenosis or occlusion; the other nine patients had no significant carotid lesions. Twenty age-matched volunteers free of neurologic symptoms or history were used as controls. Mean CBF in the sylvian region was not significantly different between patients and controls. Seven patients exhibited a focal hypoperfusion at rest in the symptomatic hemisphere, and their hypoperfused areas were hyporeactive after administration of acetazolamide. Seven other patients exhibited hyporeactive areas after acetazolamide administration while their CBF tomograms at rest were normal. Thus, CBF abnormalities were detected in 14 of the 15 patients. Our findings suggest that CBF measured early after acetazolamide administration could be useful to confirm the clinical diagnosis of TIA. In the nine patients with no significant lesion of the internal carotid artery, the areas of hypoperfusion were small and were probably related to the focal ischemic event. In the six patients with severe lesions of the internal carotid artery, abnormalities were of variable size and intensity but were often large and pronounced. The discrepancy between these two subgroups of patients could be ascribed to the hemodynamic influence of the internal carotid artery lesions. Moreover, our findings may provide some insight into the pathophysiology of TIAs. (Stroke 1989;20:458-464) 
T ransient ischemic attacks (TIAs) leave patients free of permanent neurologic dysfunction; the diagnosis is based on the patient's subjective report. Imaging as an objective measure to confirm the diagnosis could therefore be especially valuable. Current use of computed tomography (CT) has shown the presence of small hypodense ischemic areas correlating with clinical symptoms in approximately 30% of patients with TIAs. 1 -3 More recently, detection of ischemic lesions has been improved by magnetic resonance imaging (MR1). 4 Previous cerebral blood flow (CBF) studies have identified hypoperfused areas related to the clinical event 3 -7 in >40% of patients with TIAs. A test using intravenous injection of acetazolamide has shown increased hemodynamic disturbance in some patients with cerebrovascular disease. This test has been used in patients with occlusion of the internal carotid artery (ICA) who suffered a minor or severe stroke and has shown changes in the perfusion reserve before and after extracranialintracranial bypass. 8 The purpose of our work was to study CBF reactivity after administration of acetazolamide in patients with TIAs and to analyze the findings in relation to CT and angiography results. We measured CBF by single-photon emission computed tomography (SPECT) before and after administration of acetazolamide in 15 patients with recent TIAs of various etiology. We assessed the regional vasodilatory capacity of the cerebral vessels and the influence that the ischemic lesions and ICA lesions exerted on it. territory; their mean age was 62.0 (range 29-78) years. No patient had had a stroke previously and, for the patients who suffered successive attacks, all TIAs occurred in the same territory. Clinical features are given in Table 1 . The TIAs lasted from a few minutes to 20 hours. No patient had orthostatic symptoms that suggested a hemodynamic mechanism for the TIA.
All patients had CT as indicated in their clinical management. At least one CT scan was performed >72 hours after the last TIA. In five patients, we found a small hypodensity appropriate for the clinical signs; the other 10 patients had normal CT scans. Arteriography was performed in 11 patients, and the remaining four had either intravenous angiography (Patients 4 and 9) or carotid Doppler ultrasonography with spectral analysis and echotomography (Patients 2 and 6). Six of the 15 patients had severe ICA lesions; two had occlusions and four had stenoses including atheromatous lesions narrowing the artery lumen by >80% on biplane arteriograms. The remaining nine patients had no ICA lesions. Intracranial vessels were seen in the 11 patients who underwent arteriography; we did not observe any lesion of the middle cerebral artery stem, but we did see an intracranial distal rolandic occlusion in two patients (3 and 5) and a focal rolandic low flow without occlusion in one (Patient 10); intracranial vessels were normal in the remaining eight patients (1, 7, 8, (11) (12) (13) (14) (15) . Arteriography was performed between the ninth and 34th days after the last TIA, usually several days after the CBF measurement.
The localization of the ischemic event in the ICA territory was assessed from the clinical features, CT scan, and/or angiographic data. The lesion affected the right ICA territory in seven patients and the left in eight. The likely TIA mechanism was determined to be cardiac emboli in five patients, while severe ICA lesions were responsible in six others; the mechanism remained undetermined in four patients.
All patients underwent CBF measurements using SPECT. In 11, CBF was measured within 10 days after the most recent TIA; the other four patients were studied between the 15th and 30th days after the last TIA (Table 1) . We also measured CBF in 20 healthy volunteers (controls; 12 men, eight women, mean±SD age 61.7±4.4 years) without evidence of hypertension, diabetes mellitus, hyperlipidemia, cardiovascular disease, or neurologic abnormalities.
Informed consent was obtained from patients and controls. Regional CBF was assessed using a Medimatic Tomomatic 64 (Copenhagen, Denmark) and intravenous injection of xenon-133 (2220 MBeq; i.e., 60 mCi). 9 Data were simultaneously collected from three 2-cm-thick transverse slices parallel and centered at 1, 5, and 9 cm above the orbitomeatal plane (Slices 1, 2, and 3, respectively). The in-plane resolution was 1.7 cm. During the 4 minutes of data collection, patients were kept at rest with their eyes closed, and PCO2 was continuously recorded using a cutaneous electrode and a Kontron 634 Pco^ monitor (Zurich, Switzerland); the accuracy of transcutaneous Pco 2 recordings has been assessed previously. 10 A small blood sample was taken for hematocrit determination. CBF was calculated using a method described previously." For each patient, two CBF tomograms were performed on the same day, the first one with the patient at rest and the second one 1-4 hours later under the same conditions but 10 minutes after an injection of 1 g acetazolamide. 12 The controls did not receive acetazolamide injection.
The regions of interest were established from Slice 2, excluding the anterior cerebral artery and posterior cerebral artery ( Figure 1 ). The sylvian cortex was divided into three regions: the anterior (corresponding approximately to the prerolandic area), middle (corresponding to the insular area), and posterior (corresponding to the posterior temporoparietal area) regions. The sylvian subcortical region included the striatum, internal capsule, caudate, and thalamus. CBF in the sylvian cortex was obtained from the weighted average (according to the number of pixels in each region) of CBF values in the anterior, middle, and posterior sylvian regions. CBF in the total sylvian region was defined as the weighted average of CBF values in the sylvian cortex and sylvian subcortical region. The regions of interest were drawn using predefined templates adapted to each subject's head size. Since no significant difference was observed between CBF values in the right and left hemispheres of the controls, we compared the values obtained in the symptomatic hemisphere of the patients with those obtained in their asymptomatic hemisphere. CBF was calculated in each region of interest for each patient. Global reactivity to acetazolamide was expressed as the percent increase in CBF for each region.
Focal abnormalities were determined both by a visual inspection of the image of Slice 2 before and after acetazolamide using a color scale and by calculation of an index of interhemispheric asymmetry (IA=[CBF in asymptomatic-CBF in symptomatic side]-;-CBF in asymptomaticx 100) for each region of interest before and after acetazolamide administration. A focal asymmetry was considered to exist when LA was s=10. We systematically compared IA with the flow map. Most often there was no discrepancy between the calculated IA and the visual appearance of the slice although there were occasional inconsistent results. For instance, a small focal area of hypoperfusion could remain undetected by calculation because of its small size compared with the entire region of interest. Student's / test was used to assess the significance of CBF differences.
Results
Mean±SD CBF at rest in the symptomatic and asymptomatic total sylvian regions ( Table 2 ) was 47.5±13.1 and 48.6±12.1 ml/100 g/min, respectively, among the patients; the corresponding value was 53.9±7.2 ml/100 g/min in the control group's total sylvian region (difference not significant). Mean±SD Pco^ did not vary between patients (36.4±4.1 mm Hg) and controls (37.9±3.8 mm Hg), yet five patients (6, 10-12, and 15) had a CBF of <40 ml/100 g/min in both the symptomatic and asymptomatic total sylvian regions. Such low values were never observed in controls. Four of these five patients had severe ICA lesions. Mean±SD CBF at rest was lower in patients with severe ICA lesions (41.3± 11.3 ml/100 g/min) than in those without (52.9±10.6 ml/100 g/min), but the difference was not significant.
We found a focal hypoperfusion on the CBF tomogram in seven patients at rest (2,4,6,9,11, 12, and 14) . CBF maps of Patients 9 and 14 showed a clear-cut limited asymmetry that we considered to be significant, but these small asymmetries were not detected by the calculation of IA and were never observed in controls.
Reactivity to acetazolamide was >40% in most patients ( Table 2) , whereas the change in PCO2 was very small (Pco^ before acetazolamide 36.4±4.1 mm Hg, PCO2 after acetazolamide 38.4±4.1 mm Hg). Only two patients (5 and 12) had low reactivity. Patient 12 had bilateral ICA lesions, and CBF at rest was low. Patient 5 had no ICA lesion, and CBF at rest was normal. Patient 5 was normotensive, and Data are mean CBF (cerebral blood flow as ml/100 g/min) and mean increase in CBF as %. Pt, patient. nothing in his clinical history could explain such a low response to acetazolamide, which was demonstrated again in a SPECT study performed 2 months later.
After acetazolamide injection, we found CBF abnormalities in 14 patients. The focal hypoperfusions observed in the seven patients at rest were confirmed and were considerably enhanced in three patients (4, 11, and 12) . In seven patients with a normal CBF pattern at rest (1, 5, 7, 8, 10, 13, and 15) , an area of hyporeactivity appeared after acetazolamide injection, resulting in a relatively hypoperfused area on the second tomogram only. Calculated IA, as well as the visual appearance of the slices, are given in Table 3 . All CBF focal asymmetry found was hypoperfused or hyporeactive areas; we never observed hyperperfusion. We found focal asymmetries in all patients except Patient 3, who IA, index of asymmetry when a 10.0 as (cerebral blood flow in asymptomatic hemisphere region of interest-cerebral blood flow in symptomatic hemisphere region of interest)+cerebral blood flow in asymptomatic hemisphere region of interest. B, before; A, after; +, present; AS, anterior sylvian region; MS, middle sylvian region; PS, posterior sylvian region; SC, sylvian cortex (AS+MS+PS); SSC, sylvian subcortical region; TS, total sylvian region (AS+MS+PS+SSC). was explored late (30 days) after his TIA. He had a short-lasting deficit and showed no CT scan hypodensity but an occlusion of the left prerolandic artery on arteriography.
The hemispheric asymmetries we observed were of variable size and intensity, but we differentiated two groups of patients according to the calculated LA. One group comprised patients with small focal asymmetry, limited to a few regions of interest, and of <20% intensity (Patients 1,2,4-8, and 10) before or after acetazolamide injection; sylvian cortex asymmetry varied between 10.0% and 18.1%. The second group comprised patients with marked asymmetry, including most of the regions of interest, and an IA of >20% in one or more regions of interest before and/or after acetazolamide injection (Patients 11-15); sylvian cortex asymmetry varied between 16.6% and 34.5%. Severe ICA lesions were noted in all five patients of the second group. In the first group, no patient except Patient 10 had ICA lesions. Patient 10 exhibited a severe left ICA stenosis but only a 10% asymmetry in the middle sylvian region.
Discussion
In our study, TIAs were of various etiologies in patients both with and without severe ICA lesions, which differs from previous cerebral hemodynamic studies with acetazolamide 81314 although the main features of our population are otherwise comparable. The frequency of infarcts detected on CT scan (33%) is comparable with published data. 1 -3 There were also two women among our 15 patients, which corresponds to a previous study in France. 15 Earlier hemodynamic studies have demonstrated focal hypoperfused areas in the baseline condition using external stationary detectors. 1617 More recently, Hartmann 6 found regions of focal hypoperfusion in 60% of TIA patients on the day of the TIA and in 40% on the day following the TIA. Vorstrup et al, 5 using xenon-133 inhalation and SPECT, studied 14 patients with one or more TIAs and severe ICA lesions; nine patients (64%) had focal low-CBF regions and ischemic lesions were found on CT scan in four. No acetazolamide or other vasodilator was used in these studies. Of our six patients with ICA lesions, three had a hypoperfused area at rest on the CBF map.
After acetazolamide injection, we detected focal abnormalities in 14 of our 15 patients, which strongly suggests that acetazolamide significantly increases the sensitivity of SPECT for detecting pathologic areas. This has also been observed by Vorstrup et al 818 and by Kassiotis and Steinling. 19 Vorstrup et al 18 observed a low-flow area at rest in six of 27 patients presenting with TIA, while 18 of their 27 subjects had a clear-cut enhancement of their asymmetry after acetazolamide injection. Acetazolamide could be very helpful for the diagnosis of TIA, but its clinical usefulness depends on its specificity, which has not been tested. The determination of specificity requires CBF measurement after injec-tion of the drug in controls, a study that we did not perform. In nine healthy volunteers, Vorstrup et al 8 found an acetazolamide reactivity of between 13% and 43%, without any hemispheric asymmetry (S. Vorstrup, personal communication). In our study, taking the total sylvian region of the asymptomatic hemisphere, we found a reactivity to acetazolamide ranging from 8% to 102%. This great variability is not related to ICA lesions since it was also present in patients without ICA lesions ( Table 2) but could be the expression of individual sensitivity to acetazolamide, as proposed by Hauge et al. 20 Acetazolamide is a carbonic anhydrase inhibitor 12 that induces dilatation of the cerebral microvasculature. Cerebral vascular reactivity has already been studied 21 -23 using CO 2 as a vasodilator agent, showing a decrease of CBF reactivity in patients with ICA occlusions. 24 -26 Positron emission tomography in patients with TIAs and ICA lesions have provided some clues about the mechanism of the CBF hyporeactivity by showing an increase of the cerebral blood volume in the area supplied by the lesioned artery. 27 -30 This finding can be interpreted as an autoregulatory response to a decrease in blood pressure distal to an ICA lesion. Most authors have assumed that once vasodilatation has reached its upper limit, no further increase in CBF can occur. Even if the relations among blood pressure, vasodilation, and CBF are more complex, 31 -33 it can be hypothesized that within a range of low perfusion pressures, additional vasodilatation results in a limited change in CBF.
CBF hyporeactivity to acetazolamide could also be due to a chronic alteration of the microvasculature by hypertension or diabetes mellitus. In our study, two patients (5 and 12) had low CBF reactivity to acetazolamide in the asymptomatic hemisphere. Patient 12 had severe ICA lesions that could have produced CBF hyporeactivity, but Patient 5 had neither ICA lesions nor hypertension. Among the seven patients who were hypertensive (1, 7, 10, (12) (13) (14) (15) , global reactivity to acetazolamide did not differ from that of patients without hypertension.
We were able to classify our patients into two groups according to the intensity and size of the asymmetries. The first group comprised mainly patients without ICA lesions, while the second group was composed exclusively of patients with ICA lesions. Although the number of patients in our study is small, our findings may provide some insight into the mechanism of the asymmetries with regard to the presence of ICA lesions.
Nine patients were free of ICA lesions, and their hemodynamic asymmetry, when present (in eight, Patients 1, 2, 4-9) was slight. In four patients (2, 4, 6, and 9) , an area of hypoperfusion was seen at rest, and a corresponding area of hypodensity was evidenced on CT scan in three (Patients 2, 4, and 9) of these, suggesting that the hypoperfusion may be related to ischemic tissue necrosis as shown in permanent strokes. 34 In the fourth patient (6), CT scan was normal but the possibility of a small undetected infarct cannot be ruled out. The hemodynamic asymmetries evidenced at rest in these four patients were all enhanced after injection of acetazolamide. When infarction is absent (as in Patient 6), vasoparalysis is more likely than a focal diaschisis because in the latter instance reactivity to acetazolamide is expected to be normal. 35 On the other hand, four (Patients 1,5,7, and 8) of the nine patients free of ICA lesions demonstrated focal asymmetry only after acetazolamide. The mechanism of such hyporeactivity is distinct from a focal diaschisis because their tomograms were normal in baseline conditions (before acetazolamide), but the mechanism may be related to a focal vasoparalysis or to a hemodynamic disturbance when an intracerebral artery occlusion is present at the time CBF is measured. The latter hypothesis is difficult to assess in our study because arteriography was usually performed after CBF was measured and the occlusion might have already disappeared. Patients 1,7, and 8 had no cerebral vessel occlusion. Nevertheless, we found in Patient 5 a small distal occlusion in the rolandic subcortex, corresponding to the hemodynamic disturbance. In this patient a hemodynamic mechanism to explain the asymmetry is very likely. In the other three patients (1, 7, and 8), a hemodynamic mechanism cannot be definitively dismissed because of the timing of arteriography but a hemodynamic mechanism seems unlikely since distal occlusions in TIAs are notoriously rare. 2 More likely, the asymmetries resulted from a local vasoparalysis, 36 which would therefore be the most frequent mechanism of hyporeactivity we observed.
Patient 10 is the single one with large-vessel occlusive disease who responded like the nonoccluded patients. He had a left ICA stenosis of 80% on the arteriogram, which was performed the day after CBF was measured. Moreover, arteriography showed a focal rolandic area of low CBF without occlusion. Thus, we can conclude that Patient 10 has good collateral circulation and that his TIAs were probably of embolic origin.
The remaining five patients (11) (12) (13) (14) (15) who had severe ICA lesions had large and pronounced asymmetries that could have resulted from an impairment of the cerebral vascular reserve that overwhelmed the focal hypoperfused or hyporeactive areas related to the local ischemic lesion. In these patients, the rather large range of differences in CBF reactivity may depend on the efficiency of the circle of Willis anastomoses and on the pial arteries to compensate for the defect in hemispheric blood supply. The large asymmetries seen at rest in Patients 11, 12, and 14 may be related to diaschisis. However, according to Rancurel et al, 35 the enhancement of asymmetry after injection of acetazolamide that we observed in these patients does not favor this hypothesis. It may be that we observed both diaschisis and the hemodynamic consequence of large-vessel occlusive dis-ease. On the other hand, when asymmetry appears only after administration of acetazolamide (as in Patients 13 and 15), a diaschisis cannot be suspected and asymmetry should therefore be related to a hemodynamic mechanism.
Although we have no absolute arguments for the pathophysiologic mechanism (embolic or hemodynamic) of TIAs, some insights can be deduced from our findings. Although all five patients (11) (12) (13) (14) (15) developed a large and significant asymmetry after acetazolamide, we never observed an absence of response or a negative response to the drug. Thus, none of our patients were in a critical hemodynamic state at the time we measured CBF. The collateral circulation was sufficient, if not perfect, to permit a reduced but positive acetazolamide response. Moreover, we have no clinical arguments for the hemodynamic hypothesis (no orthostatic symptoms). Even when an ICA occlusion is present (as in Patients 12 and 14), a TIA of hemodynamic origin cannot be affirmed. Patient 14 had a large acetazolamideinduced asymmetry, but his CBF at rest was 64 ml/ 100 g/min in the symptomatic total sylvian region, which is far from the critical level of ischemia; an embolic mechanism from the occluded artery must be suspected in this patient. In contrast, Patient 12 had both a low acetazolamide reactivity and a low CBF at rest (25 ml/100 g/min). He was probably closer to a critical level of ischemia than Patient 14 at the moment of CBF measurement and is actually the only patient in whom a hemodynamic TIA may be suspected. We conclude that most TIAs in our series related to a carotid pathology were of embolic origin. However, further studies are necessary to assess the specificity and the clinical usefulness of these findings.
